RxDoctor Payments Data

On Lau, MD

Internal Medicine · New York, NYNPI 1033165345

Payments from drug & device makers

$659in general payments, 2019–2025

Across 35 payments — averaging $18.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$290
  • AbbVie$150
  • Johnson & Johnson$91
  • Seqirus USA Inc$63
  • Amgen$51
  • AstraZeneca$13

What the payments were for

  • Food & beverage$64598%
  • Education$142%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK17$290
AbbVie(2 entities)9$150
Johnson & Johnson2$91
Seqirus USA Inc3$63
Amgen(2 entities)3$51
AstraZeneca1$13

How this compares

$659 in reported general payments places this provider in the 65th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$59,145
Medicare patients
103
Services billed
763

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin345$380,610
VascepaIcosapent Ethyl405$176,042
JanuviaSitagliptin Phosphate107$108,263
Diclofenac Epolamine154$101,899
RybelsusSemaglutide52$98,991
LinzessLinaclotide95$92,905
FarxigaDapagliflozin Propanediol84$91,735
VemlidyTenofovir Alafenamide55$89,703
TradjentaLinagliptin70$82,136
OzempicSemaglutide57$65,038
JanumetSitagliptin Phos/Metformin Hcl72$63,555
Trelegy ElliptaFluticasone/Umeclidin/Vilanter67$54,621
MounjaroTirzepatide40$45,992
MyrbetriqMirabegron48$43,308
EliquisApixaban46$40,648

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Shingrix, Incruse Ellipta$290$114,072206 claims
AbbVieLinzess, Creon$150$112,719113 claims
AstraZenecaFarxiga, Symbicort$13$103,036124 claims
Johnson & JohnsonXarelto$91$38,06630 claims
AmgenProlia$51$25,54615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →